ESMO GI Congress 2026: key results and trends
What the 575 abstracts at ESMO GI Congress 2026 reported, drug by drug: the readouts that stood out and the targets and modalities that dominated, and how this edition compares with earlier years.
- abstracts
- 575
- drug-linked abstracts
- 311
- companies
- 55
- from Phase 3 studies
- 30
Drug-linked abstracts by phase
- Phase 1 18
- Phase 1/2 10
- Phase 2 45
- Phase 2/3 5
- Phase 3 30
Key results
Quotes are taken verbatim from each abstract's results; selection is automated. Report an issue
tremelimumab
Tumour response analyses by RECIST v1.1 and mRECIST in the phase III EMERALD-3 study of tremelimumab plus durvalumab with or without lenvatinib plus transarterial chemoembolisation (TACE) in embolisation-eligible hepatocellular carcinoma (eeHCC)
Read the abstract (opens in a new tab)PFS per RECIST v1.1 by BICR showed a statistically significant improvement for STRIDE + L + TACE vs TACE (HR, 0.70 [95% CI, 0.57–0.86]; p=0.0007) at DCO1 (2 Sep 2025) and a clinically meaningful improvement for STRIDE + TACE vs TACE (0.71 [0.56–0.91]) at DCO2.
adagrasib
Second-line adagrasib plus cetuximab vs chemotherapy in patients with KRASG12C-mutated metastatic colorectal cancer: Results from the KRYSTAL-10 trial
Read the abstract (opens in a new tab)Median PFS per BICR was 7.5 mo with Ada + Cetux vs 8.1 mo with chemo (HR 0.89 [95% CI 0.71–1.13]; P = 0.32).
nivolumab
Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line (1L) treatment for unresectable hepatocellular carcinoma (uHCC): 4-year (yr) follow-up (FU) expanded analyses in the Chinese population of CheckMate 9DW
Read the abstract (opens in a new tab)Objective response rate was higher with NIVO + IPI (37%) vs LEN/SOR (16%) and median duration of response was 39.4 and 7.2 mo in NIVO + IPI and LEN/SOR arms, respectively.
durvalumab
Immune-mediated adverse events (imAEs) in MATTERHORN: A phase III study of durvalumab (D) plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric/gastroesophageal junction (G/GEJ) adenocarcinoma
Read the abstract (opens in a new tab)EFS improved with D + FLOT in pts with (HR 0.62; 95% CI 0.40–0.91) and without imAEs (HR 0.70; 95% CI 0.53–0.90) vs P + FLOT.
zolbetuximab
Zolbetuximab plus gemcitabine and nab-paclitaxel (GN) in patients (pts) with claudin 18 isoform 2 (CLDN18.2)+ metastatic pancreatic adenocarcinoma (mPAC): phase II GLEAM study
Read the abstract (opens in a new tab)Median OS was 13.7 vs 13.6 months with zolbetuximab + GN vs GN; HR, 1.00 (95% CI, 0.78–1.29); P = 0.499.
regorafenib
VIVA trial: Randomized comparison of adjuvant regorafenib plus durvalumab versus observation in stage IV colorectal cancer with no evidence of disease
Read the abstract (opens in a new tab)Median OS was not reached in REGO-DURVA vs 43.6 months in OBS (HR 0.85; 95% CI: 0.29–2.44; p=0.76).
cadonilimab
Cadonilimab plus bevacizumab and mFOLFOX6 as first-line treatment for advanced unresectable MSS, RAS-mutant metastatic colorectal cancer: Results from a multicenter, open-label, phase II study (BECOME3)
Read the abstract (opens in a new tab)The ORR in BECOME3 reached 64.2% (including 5.7% complete responses), compared to 54.5% (0.8% CR) in the bevacizumab-chemotherapy group of BECOME.
ulenistamab
First-in-human phase I/IIa study of ulenistamab (PBP1510), an anti-PAUF monoclonal antibody, in metastatic pancreatic adenocarcinoma
Read the abstract (opens in a new tab)In combination cohorts (N=18), 13 patients (72.2%) experienced PBP1510-related TRAEs, predominantly Grade 1–2 (66.7%); the most common (>15%) were anaemia, diarrhoea, and nausea.
Trends at ESMO GI 2026
Small molecules were the most frequent modality (57% of drug-linked abstracts). TS was the most frequent target (20%). Colorectal cancer (CRC) was the most frequent disease (23%).
What the abstracts covered
Share of the 311 drug-linked abstracts, by the target, modality, disease and company of each drug. An abstract can count in more than one row, so a list can add up to more than 100%.
- Antibody-drug conjugates5%14 drug-linked abstracts
Top targets
- TS6120%
- CD2745618%
- PDCD13612%
- TOP1279%
- TUBB217%
- ERBB2145%
- TYMP124%
- VEGFR2124%
- EGFR103%
- VEGFA103%
Top modalities
- Small molecules17857%
- Monoclonal antibodies14747%
- Antibody-drug conjugates145%
- Bispecific antibodies72%
- Peptides72%
- Natural-product mixtures and botanicals62%
- Radiopharmaceuticals52%
- Non-antibody therapeutic proteins41%
Top diseases
- Colorectal cancer (CRC)7023%
- Hepatocellular carcinoma (HCC)4414%
- Pancreatic adenocarcinoma (PDAC)3612%
- Gastric cancer (GC)289%
- Gastroesophageal junction adenocarcinoma258%
- Biliary cancer227%
- Gastric adenocarcinoma206%
- Metastatic colon cancer (mCRC)175%
- Esophageal Squamous Cell Carcinoma (ESCC)165%
- Pancreatic cancer (PC)155%
Most active companies
- Genentech3612%
- AstraZeneca3110%
- Bristol Myers Squibb289%
- Eli Lilly165%
- Taiho Pharmaceutical145%
- Pfizer103%
- Sanofi103%
- Roche83%
- Assertio72%
- Servier72%
ESMO GI over the years
- 2026575 abstracts · this edition
- 2025360 abstracts
Explore every ESMO GI 2026 result in Gosset
All 311 drug-linked abstracts, joined to each drug’s trials, targets, developers and deals, with a source behind every line.
This page shows a sample of results. Gosset has the abstracts from this meeting and 100+ others; reach out for full access.